Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

With yet another quarter where Pfizer handily beat consensus earnings expectations, it’s even more clear that CEO Albert Bourla is already well on his way toward getting Pfizer back on track ...

Merck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its poor public perception. In an interview with Yahoo Finance, Frazier defended the industry’s ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

WEST LAFAYETTE, Ind. — Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17) the launch of the Young Institute Pharmaceutical Manufacturing ...

a TGF-beta-targeting PAH drug Merck acquired via its $11.5 billion takeover of Acceleron Pharma last year. Sotatercept is in phase 3 testing as an add-on therapy for PAH, and according to Merck ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more T-shirts are quintessential for any wardrobe, regardless of the season. They're a classic top on their ...